Abstract
Maintenance of health depends on the ability to respond appropriately to environmental Stressors via reciprocal interactions between the body and the brain. In this context, it is well recognized that the pineal hormone melatonin (MLT) plays an important role. T-helper cells bear G-protein-coupled MLT cell membrane receptors and, perhaps, MLT nuclear receptors. Activation of MLT receptors enhances the release of T-helper cell cytokines, such as γ-interferon and interleukin-2 (IL-2), as well as activation of novel opioid cytokines which crossreact immunologically with both interleukin-4 and dynorphin B. MLT has been reported also to enhance the production of interleukin-1, interleukin-6 and interleukin-12 in human monocytes. These mediators may counteract secondary immunodeficiences, protect mice against lethal viral and bacterial diseases, synergize with IL-2 against cancer and influence hematopoiesis. Hematopoiesis is influenced by MLT-induced-opioids (MIO) acting on kappa 1-opioid receptors present on bone marrow macrophages. Clinically, MLT could amplify the anti-tumoral activity of low dose IL-2, induce objective tumor regression, and prolong progression-free time and overall survival. MLT seems to be required for the effectiveness of low dose IL-2 in those neoplasias that are generally resistant to IL-2 alone. Similar findings were obtained in a study in which MLT was combined with γ-interferon in metastatic renal cell carcinoma. In addition, MLT in combination with low-dose IL-2 was able to neutralize the surgery-induced lymphocytopenia in cancer patients. IL-2 treatment in patients results in activation of the immune system and creates the most suitable biological background for MLT. The finding that MLT stimulates IL-12 production from human monocytes only if incubated in presence of IL-2 further supports this concept. On the other hand, high concentrations of MLT have been found in human breast cancer tissue. The MLT concentration, which was 3 orders of magnitude higher than that present in the plasma, correlated positively with good prognostic markers such as estrogen receptor status and nuclear grade. Whether this relates to the imunoneuroendocrine action of MLT remains to be established. Clinical studies are needed on the effect of MLT in combination with IL-2 or other cytokines in cancer patients and viral diseases including HIV-infected patients.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anwar, M.M., Mahfouz, H.A., and Sayed, A.S., 1998, Potential protective effects of melatonin on bone marrow of rats exposed to cytotoxic drugs, Comp. Biochem. Physiol. 119:493–591.
Banks, R.E., Patel, P.M., and Selby, P.J., 1995, Interleukin-12: a new player in cytokine therapy, Br. J. Cancer 71:655–659.
Bartsch, C. and Bartsch, H., 1993, Melatonin secretion in oncological patients: current results and methodological considerations, in: Advances in Pineal Research 7 (G.J.M. Maestroni and A.R.J. Reiter, eds.), pp. 283–301, John Libbey, London.
Becker, J., Veit, G., Handgretinger, R., Attanasio, G., Bruchett, G., Trenner, I., Niethammer, D., and Gupta, D., 1988, Circadian variations in the immunomodulatory role of the pineal gland, Neuroendocrinol. Lett. 10:65–80.
Ben-Nathan, D., Maestroni, G.J.M., and Conti, A., 1995, Protective effect of melatonin in mice infected with encephalitis viruses, Arch. Virol. 140:223–230.
Ben-Nathan, D., Maestroni, G.J.M., and Conti, A., 1996, Protective effect of melatonin in viral and bacterial infections, Abstract, 2nd Locarno Meeting on Neuroendocrinoimmunology. Therapeutic potential of the Pineal Hormone Melatonin, May 5-8, Locarno, Switzerland.
Blask, D.E., 1984, The pineal: an oncostatic gland?, in: The Pineal Gland (R.J. Reiter, ed.), pp. 253–285, Raven Press, New York.
Blask, D.E., 1993, Melatonin in oncology, in: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 447–477, CRC Press, Boca Raton.
Bonilla, E., Valerofuenmajor, N., Pons, H., and Chacin-Bonilla, L., 1997, Melatonin protects mice infected with Venezuelan equine encephalomyelitis virus, Cell Mol. Life Sci. 53:430–434.
Carlberg, C. and Wiesenberg, I., 1995, The orphan receptor family RZR/ROR, melatonin and 5-lipoxygenase: an unexpected relationship, J. Pineal Res. 18:171–178.
Caroleo, M.C., Frasca, D., Nistico, G., and Doria, G., 1992, Melatonin as immunomodulator in immunodeficient mice, Immunopharmacology 23:81–89.
Champney, T.H. and McMurray, D.N., 1991, Spleen morphology and lymphoproliferative activity in short photoperiod exposed hamsters, in: Role of melatonin and pineal peptides in neuroimmunomodulation (F. Fraschiniand and R.J. Reiter, eds.), pp. 219–225, Plenum Publ Co, London.
Colombo, L.L., Chen, G.-J., Lopez, M.C., and Watson, R.R., 1992, Melatonin induced increase in gammainterferon production by murine splenocytes, Immunol. Lett. 33:123–126.
Conti, A., Haran-Ghera, N., and Maestroni, G.J.M., 1992, Role of pineal melatonin and melatonin-induced immuno-opioids in murine leukemogenesis, Med. Oncol. Tumor Pharmacoth. 9:87–92.
Conti, A. and Maestroni, G.J.M., 1995, The clinical neuroimmunotherapeutic role of melatonin in oncology, J. Pineal Res. 19:103–110.
Del Gobbo, V., Libri, V., Villani, N., Caliò, R., and Nstico, G., 1989, Pinealectomy inhibits interleukin-2 production and natural killer activity in mice, Int. J. Immunopharmacol. 11:567–577.
Del Prete, G., Maggi, E., and Romagnani, S., 1994, Human Thl and Th2 cells: Functional properties, mechanisms of regulation and role in disease, Lab. Invest. 70:299–307.
Garcia-Mauriño, S., Gonzales-Haba, M.G., Calvo, J.R., Rafii-El-Idrissi, M., Sanchez-Margalet, V., Goberna, R., and Guerrero, J.M., 1997, Melatonin enhances IL-2, 11-6, and IFN-γ production by human circulating CD4+ cells., J. Immunol. 159:574–581.
Garcia-Perganeda, A., Pozo, D., Guerrero, J.M., and Calvo, J.R., 1997, Signal transduction for melatonin in human lymphocytes. Involvement of a pertussis toxin-sensitive G protein, J. Immunol. 159:3774–3781.
Giordano, M. and Palermo, M.S., 1991, Melatonin-induced enhancement of antibody dependent cellular cytotoxicity, J. Pineal Res. 10:117–121.
Guerrero, J.-M., Garcia-Maurino, S., Gil-Haba, M., Rafii-El-Idrissi, M., Pozo, D., Garcia-Perganeda, A., and Calvo, J.R., 1996, Mechanisms of action on the human immune system: Membrane receptors versus nuclear receptors, in: Therapeutic potential of the Pineal Hormone Melatonin, vol. 23 (G.J.M. Maestroni, A. Conti, and R.J. Reiter, eds.), Frontiers of Hormone Research, p. 43–52, Karger, Basal.
Haldar, C., Haussler, D., and Gupta, D., 1992, Response of CFU-GM (colony forming units for granulocytes and macrophages) from intact and pinealectomized rat bone marrow to macrophage colony stimulating factor (rGM-CSF) and human recombinant erythropoietin (rEPO), Prog. Brain Res. 91:323–325.
Hansson, I., Holmdahl, R., and Mattsson, R., 1992, The pineal hormone melatonin exaggerates development of collagen-induced arthritis in mice, J. Neuroimmunol. 39:23–31.
Hiddinga, H.J., Isaak, D.D., and Lewis, R.V., 1994, Enkephalin-containing peptides processed from proenkephalin significantly enhance the antibody-forming cell responses to antigens, J. Immunol. 152:3748–3758.
Hofbauer, L.C. and Heufelder, A.E., 1996, Endocrinology meets immunology: T lymphocytes as novel targets for melatonin, Eur. J. Endocrinol. 134:424–425.
Iguchi, H., Kato, H., and Ibayashi, H., 1982, Age-dependent reduction in serum melatonin concentrations in healthy subjects, J. Clin. Endocrinol. Metab. 55:27–32.
Konakchieva, R., Kyurkchiev, S., Kehayov, I., Taushanova, P., and Kanchev, L., 1995, Selective effect of methoxyndoles on the lymphocyte proliferation and melatonin binding to activated human lymphoid cells, J. Neuroimmunol. 63:125–132.
Lissoni, P., Pittalis, S., Barni, S., Rovelli, F., Fumagalli, L., and Maestroni, G.J.-M., 1997a, Regulation of interleukin-2/interleukin-12 interactions by the pineal gland, Int. J. Thymology 5:443–447.
Lissoni, P., Rovelli, F., Brivio, F., Pittalis, S., Maestroni, G.J.M., and Fumagalli, L., 1997b, In vivo study of the modulatory effect of the pineal hormone melatonin on interleukin-12 secretion in response to interleukin-2, Int. J. Thymology 5:482–486.
Lissoni, P., Tisi, E., Barni, S., Ardizzoia, A., Rovelli, F., Rescaldani, R., Ballabio, D, Benenti, G., Angeli, M., Tancini, G., Conti, A., and Maestroni, G.J.M., 1992, Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer, Br. J. Cancer 66:155–158.
Maestroni, G., Hertens, E., Galli, P., Conti, A., and Pedrinis, E., 1996, Melatonin-induced T-helper cell hematopoietic cytokines resembling both interleukin-4 and dynorphin, J. Pineal Res. 21:131–139.
Maestroni, G.J.M., 1993, The immunoneuroendocrine role of melatonin, J. Pineal Res. 14:1–10.
Maestroni, G.J.M., 1998, Kappa-opioid receptors in marrow stroma mediate the hematopoietic effects of melatonin-induced opioid cytokines, Ann. N Y Acad. Sci. 840:411–420.
Maestroni, G.J.M. and Conti, A., 1989, Beta-endorphin and dynorphin mimic the circadian immunoenhancing and anti-stress effects of melatonin, Int. J. Immunopharmacol. 11:333–340.
Maestroni, G.J.M. and Conti, A., 1990, The pineal neurohormone melatonin stimulates activated CD4+, Thy-1+ cells to release opioid agonist(s) with immunoenhancing and anti-stress properties, J. Neuroimmunol. 28:167–176.
Maestroni, G.J.M. and Conti, A., 1991, Anti-stress role of the melatonin-immuno-opioid network. Evidence for a physiological mechanism involving T cell-derived, immunoreactive ß-endorphin and enkephalin binding to thymic opioid receptors, Int. J. Neurosci. 61:289–298.
Maestroni, G.J.M. and Conti, A., 1993, Melatonin in relation to the immune system, in: Melatonin. Biosynthesis, Physiological effects and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 290–306, CRC Press, Boca Raton.
Maestroni, G.J.M. and Conti, A., 1996, Melatonin in human breast cancer tissue: Association with nuclear grade and estrogen receptor status, Lab. Invest. 75:557–561.
Maestroni, G.J.M., Conti, A., and Lissoni, P., 1994a, Colony-stimulating activity and hematopoietic rescue from cancer chemothereapy compounds are induced by melatonin via endogenous interleukin 4, Cancer Res. 54:4740–4743.
Maestroni, G.J.M., Conti, A., and Pierpaoli, W., 1986, Role of the pineal gland in immunity. Circadian synthesis and release of melatonin modulates the antibody response and antagonize the imunosuppressive effect of corticosterone, J. Neuroimmunol. 13:19–30.
Maestroni, G.J.M., Conti, A., and Pierpaoli, W., 1987, Role of the pineal gland in immunity: II. Melatonin enhances the antibody response via an opiatergic mechanism, Clin. Exp. Immunol. 68:384–391.
Maestroni, G.J.M., Covacci, V., and Conti, A., 1994b, Hematopoietic rescue via T-cell-dependent, endogenous GM-CSF by the pineal neurohormone melatonin in tumor bearing mice, Cancer Res. 54:2429–2432.
Maestroni, G.J.M., Flamigni, L., Hertens, E., and Conti, A., 1995, Biochemical and functional characterization of melatonin-induced opioids in spleen and bone marrow T-helper cells, Neuroendocrinol. Lett. 17:145–153.
Maestroni, G.J.M. and Pierpaoli, W., 1981, Pharmacological control of the hormonally modulated immune response, in: Psychoneuroimmunology, vol. I (R. Ader, ed.). pp. 405–425, Academic Press, New York.
Morrey, M.K., McLachlan, J.A., Serkin, C.D., and Bakouche, O., 1994, Activation of human monocytes by the pineal neurohormone melatonin, J. Immunol. 153:2671–2680.
Neri, B., De Leonardis, V., Gemelli, M.T., DiLoro, M., Mottola, A., Ponchietti, R., Raugei, A., and Cini, G., 1998, Melatonin as biological response modifier in cancer patients, Anticancer Res. 18:1329–1332.
Neri, B., Fiorelli, C., Moroni, F., Nicita, G., Paoletti, M.C., Ponchietti, R., Raugei, A., Santoni, G., Trippitelli, A., and Grechi, G., 1994, Modulation of human lymphoblastoid interferon activity by melatonin in metastatic renal cell carcinoma. A phase II study, Cancer 73:3015–3019.
Palermo, M.S., Vermeulen, M., and Giordano, M., 1994, Modulation of antibody-dependent cellular cytotoxicity by pineal gland, in: Advances in Pineal Research, vol. 7 (G.J.M. Maestroni, A. Conti, R.J. Reiter, eds.), pp. 143–147, John Libbey, London.
Pioli, C., Caroleo, M.C., Nistico, G., and Doria, G., 1993, Melatonin increases antigen presentation and amplifies specific and non specific signals for T-cell proliferation, Int. J. Immunopharmacol. 15:463–469.
Poon, A.M., Liu, Z.M., Pang, C.S., Brown, G.M., and Pang, S.F., 1994, Evidence for a direct action of melatonin on the immune system, Biol. Signals 3:107–117.
Wichmann, M., Zellweger, R., De Maso, A., Ayala, A., and Chaudry, I., 1996, Melatonin administration attenuates depressed immune functions trauma-hemorrhage, J. Surg. Res. 63:256–262.
Young, M.R.I., Young, M.E., and Kim, K., 1988, Regulation of tumor-induced myelopoiesis and the associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma by prostaglandin E2, Cancer Res. 48:6826–6831.
Yu, H.-S., Tsin, A.T.C., and Reiter, R.J., 1993, Melatonin: History, Biosynthesis, and Assay Methodology, in: Melatonin. Biosynthesis, Physiological Effects, and Clinical Applications (H.-S. Yu and R.J. Reiter, eds.), pp. 1–17, CRC Press, Boca Raton.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Science+Business Media New York
About this chapter
Cite this chapter
Maestroni, G.J.M. (1999). Therapeutic Potential of Melatonin in Immunodeficiency States, Viral Diseases, and Cancer. In: Huether, G., Kochen, W., Simat, T.J., Steinhart, H. (eds) Tryptophan, Serotonin, and Melatonin. Advances in Experimental Medicine and Biology, vol 467. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4709-9_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-4709-9_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-7133-5
Online ISBN: 978-1-4615-4709-9
eBook Packages: Springer Book Archive